Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Pharaon

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Biomedicines|January 21, 2023
Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer ProgressionAmanda Reyes, Atish Mohanty, Rebecca Pharaon, et al.
Journal of Thoracic Disease|November 4, 2020
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequenceRebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, et al.
Cancers|June 28, 2023
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?Amanda Reyes, Rebecca Pharaon, Atish Mohanty, et al.
Translational Lung Cancer Research|June 19, 2025
Neoadjuvant tepotinib in stage IIB N0 non-small cell lung carcinoma with <i>MET</i> exon 14 skipping mutation: a case report and review of the literatureAmanda Reyes, Rebecca Pharaon, Atish Mohanty, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
Journal of Thoracic Disease|November 4, 2020
Biomarkers in immunotherapy: literature review and future directionsRebecca Pharaon, Maria A Koczywas, Sabrina Salgia, et al.
Medicine|November 12, 2020
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case reportJeremy Fricke, Isa Mambetsariev, Rebecca Pharaon, et al.
Journal of Clinical Medicine|June 19, 2020
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy StrategiesSwapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, et al.
Advances in Cancer Research|June 29, 2020
MET receptor in oncology: From biomarker to therapeutic targetRaeva Malik, Isa Mambetsariev, Jeremy Fricke, et al.
Oncotarget|July 26, 2018
Heuristic value-based framework for lung cancer decision-makingIsa Mambetsariev, Rebecca Pharaon, Arin Nam, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Biomedicines|January 21, 2023
Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer ProgressionAmanda Reyes, Atish Mohanty, Rebecca Pharaon, et al.
Journal of Thoracic Disease|November 4, 2020
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequenceRebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, et al.
Cancers|June 28, 2023
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?Amanda Reyes, Rebecca Pharaon, Atish Mohanty, et al.
Translational Lung Cancer Research|June 19, 2025
Neoadjuvant tepotinib in stage IIB N0 non-small cell lung carcinoma with <i>MET</i> exon 14 skipping mutation: a case report and review of the literatureAmanda Reyes, Rebecca Pharaon, Atish Mohanty, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
Journal of Thoracic Disease|November 4, 2020
Biomarkers in immunotherapy: literature review and future directionsRebecca Pharaon, Maria A Koczywas, Sabrina Salgia, et al.
Medicine|November 12, 2020
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case reportJeremy Fricke, Isa Mambetsariev, Rebecca Pharaon, et al.
Journal of Clinical Medicine|June 19, 2020
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy StrategiesSwapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, et al.
Advances in Cancer Research|June 29, 2020
MET receptor in oncology: From biomarker to therapeutic targetRaeva Malik, Isa Mambetsariev, Jeremy Fricke, et al.
Oncotarget|July 26, 2018
Heuristic value-based framework for lung cancer decision-makingIsa Mambetsariev, Rebecca Pharaon, Arin Nam, et al.
Pageof 3